Excellent
Aligned
Patient Risk:
Low
Summary
The AI claim matches the label’s Warning (5.2) stating increased endometrial cancer risk with unopposed estrogen in women with a uterus, including the reported relative risk range and dependence on duration/dose, and is consistent with the label’s statement that adding a progestogen reduces risk.
Category Scores
Accurate Statements
Unopposed estrogen in women with a uterus increases endometrial cancer risk.
Section 5.2 — Malignant Neoplasms (Endometrial Cancer): “An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus.”
The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users and appears dependent on duration of treatment and on estrogen dose.
Section 5.2 — Malignant Neoplasms (Endometrial Cancer): “about 2 to 12 times greater… appears dependent on duration… and on estrogen dose.”
Adding a progestogen to estrogen-alone therapy reduces endometrial cancer risk by reducing endometrial hyperplasia.
Section 5.2 — Malignant Neoplasms (Endometrial Cancer): “Adding a progestogen to estrogen-alone therapy has been shown to reduce the risk of endometrial hyperplasia…”; and Section 2.1 — Important Use Information: progestogen reduces endometrial cancer risk.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated statement(s) accurately reflect label warning information about endometrial cancer risk with unopposed estrogen in women with a uterus and the risk-reduction rationale for adding a progestogen.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Aligned
Primary Issue
Suggested Improvement